A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development.
Key RequirementsClinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.
Be age 18-75
Have HS for at least 12 months
Have HS lesions in at least 2 different parts of the body
Have not responded to or tolerated 28-day course of oral antibiotics
Agree to use topical antiseptics daily
Participants Must Not:
Have had surgical treatment for HS in the last 4 weeks before randomization
Have an active skin disease or condition that could interfere with the assessment of HS
Have a history of chronic alcohol abuse or drug abuse or other illicit drug abuse 1 year before screening
Lilly Trial Alerts
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo